From IV hydration to mental health support, the clinic is devoted to helping the community live better, one patient at a time ...
Clinical stage biotech Tryptamine Therapeutics has achieved a major milestone in the development of its novel IV-infused ...
Special Report: Clinical-stage biotech Tryptamine Therapeutics has achieved a key milestone, successfully completing the ...
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home ...
IV drips for hangovers are becoming a flashy trend, but experts warn they may strain vital organs. While they might look ...
As we continually discover new ways to harness emerging AI technology, AI computing clusters are at the front end of a huge ...
Total Revenue -- $21.2 million for the third quarter of 2025, up 16%, driven by MRI compatible IV infusion pump and ...
The company is deeply embedded in hospital operations, with a large installed base of equipment and a broad consumables ...
Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...
A phase 2 study reveals high efficacy and manageable safety of venetoclax plus obinutuzumab for untreated CLL/SLL in Japanese ...
The Hill Helicopters’ fully composite structure HX50 rotorcraft uses oven consolidation and splice joining for a ...
1d
Urbanfund Corp.: Report on Financial Results for the Three and Nine Months Ended September 30, 2025
Mitchell Cohen, Chief Executive Officer and President of Urbanfund Corp. (TSX-V: UFC) ("Urbanfund" or the "Company"), confirmed today that the Company has filed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback